You are here: Industry Insights > COPD

News List

World COPD deaths rise 12 percent in 15 years pharmatimes
August 18, 2017
Study found that the number of people dying from COPD up nearly 12 percent over a 15-year period.
Verona Pharma begins dosing RPL554 in Phase IIb COPD trial pharmatimes
July 27, 2017
Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease
EU nod for Chiesi’s COPD therapy pharmatimes
July 27, 2017
European regulators have green-lighted Chiesi’s new chronic obstructive pulmonary disease (COPD) maintenance therapy Trimbow.
Theravance COPD drug clears safety study, setting up NDA fiercebiotech
July 21, 2017
Theravance Biopharma and Mylan are still on course to file for approval of their nebulized chronic obstructive pulmonary disease (COPD) therapy in the fourth quarter after posting 12-month safety data.
Positive results from 12-month Phase III safety study of Revefenacin in patients with COPD cphi-online
July 21, 2017
These data, combined with positive results from two Phase III efficacy studies, support NDA filing planned for fourth quarter of 2017.
NICE turnaround for AstraZeneca’s COPD drug Daxas pharmatimes
June 26, 2017
AstraZeneca’s Daxas is now likely to be routinely available on the NHS to patients with chronic obstructive pulmonary disease (COPD), after new evidence helped persuade cost regulators that the drug offers value for money in this setting.
COPD market set to hit $14.1 billion by 2025: GlobalData expressbpd
June 12, 2017
COPD market set to hit $14.1 billion by 2025
New analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated wi cphi-online
May 25, 2017
New analyses from the FLAME study suggest dual bronchodilator Ultibro Breezhaler provides similar or better efficacy versus steroid-containing therapies, regardless of blood eosinophil counts.
Launch of Utibron Neohaler in the US cphi-online
April 05, 2017
Represents the latest combination therapy now available for the millions of patients living with COPD in the US.
Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape and therapeutics market review h2 20 pharmaasia
March 06, 2017
Global Markets Direct provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page